Literature DB >> 31383966

A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma.

Kirill A Lyapichev1, Sergio Piña-Oviedo2, L Jeffrey Medeiros1, Mark G Evans3, Hui Liu4, Alonso R Miranda5, Kelly K Hunt6, Mark W Clemens7, John M Stewart8, Mitual B Amin9, Andres E Quesada10, Siaw Ming Chai11, Arianna Di Napoli12, Arthy Yoga13, Sanat K Dave1, Ignacio I Wistuba14, Yun Wu8, Carlos E Bueso-Ramos1, Ellen J Schlette1, Maria C Ferrufino-Schmidt14, Sanam Loghavi1, Joseph D Khoury1, Ken H Young1, Roberto N Miranda15.   

Abstract

Breast implant anaplastic large cell lymphoma is an entity recently recognized by the World Health Organization. The tumor arises around textured-surface breast implants and is usually confined to the surrounding fibrous capsule. Currently, there are no recommendations for handling and sampling of capsules from patients with suspected breast implant anaplastic large cell lymphoma without a grossly identifiable tumor. We analyzed complete capsulectomies without distinct gross lesions from patients with breast implant anaplastic large cell lymphoma. The gross appearance of the capsules as well as the presence, extent and depth of tumor cells on the luminal side and number of sections involved by lymphoma were determined by review of routine stains and CD30 immunohistochemistry. We then used a mathematical model that included the extent of tumor cells and number of positive sections to calculate the minimum number of sections required to identify 95% of randomly distributed lesions. We identified 50 patients with breast implant anaplastic large cell lymphoma who had complete capsulectomies. The implants were textured in all 32 (100%) cases with available information. Anaplastic large cell lymphoma was found in 44/50 (88%) capsules; no tumor was found in six (12%) patients who had lymphoma cells only in the effusion. The median number of sections reviewed was 20 (range, 2-240), the median percentage of sections involved by tumor was 6% (range, 0-90%), and the median percentage of sections involved by lymphoma was 10% (range, 0-90%). Invasion deep into or through the capsule was identified in 18/50 (36%) patients. In patients with breast implant anaplastic large cell lymphoma without a grossly identifiable tumor we identified a spectrum of involvement and we propose a protocol for handling, sampling and reporting these cases. The number of sections to exclude the presence of lymphoma with more than 95% certainty was supported by a mathematic rationale.

Entities:  

Year:  2019        PMID: 31383966      PMCID: PMC7489290          DOI: 10.1038/s41379-019-0337-2

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  16 in total

1.  Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant.

Authors:  J A Keech; B J Creech
Journal:  Plast Reconstr Surg       Date:  1997-08       Impact factor: 4.730

Review 2.  Breast implant-associated anaplastic large cell lymphoma: a systematic review.

Authors:  Courtney A Gidengil; Zachary Predmore; Soeren Mattke; Kristin van Busum; Benjamin Kim
Journal:  Plast Reconstr Surg       Date:  2015-03       Impact factor: 4.730

3.  Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma Etiology and Epidemiology (PROFILE): Initial Report of Findings, 2012-2018.

Authors:  Colleen M McCarthy; Nilsa Loyo-Berríos; Ali A Qureshi; Erin Mullen; Gayle Gordillo; Andrea L Pusic; Binita S Ashar; Katie Sommers; Mark W Clemens
Journal:  Plast Reconstr Surg       Date:  2019-03       Impact factor: 4.730

4.  Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma.

Authors:  Mark W Clemens; L Jeffrey Medeiros; Charles E Butler; Kelly K Hunt; Michelle A Fanale; Steven Horwitz; Dennis D Weisenburger; Jun Liu; Elizabeth A Morgan; Rashmi Kanagal-Shamanna; Vinita Parkash; Jing Ning; Aliyah R Sohani; Judith A Ferry; Neha Mehta-Shah; Ahmed Dogan; Hui Liu; Nora Thormann; Arianna Di Napoli; Arianna DiNapoli; Stephen Lade; Jorge Piccolini; Ruben Reyes; Travis Williams; Colleen M McCarthy; Summer E Hanson; Loretta J Nastoupil; Rakesh Gaur; Yasuhiro Oki; Ken H Young; Roberto N Miranda
Journal:  J Clin Oncol       Date:  2015-11-30       Impact factor: 44.544

5.  Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients.

Authors:  Roberto N Miranda; Tariq N Aladily; H Miles Prince; Rashmi Kanagal-Shamanna; Daphne de Jong; Luis E Fayad; Mitual B Amin; Nisreen Haideri; Govind Bhagat; Glen S Brooks; David A Shifrin; Dennis P O'Malley; Chan Y Cheah; Carlos E Bacchi; Gabriela Gualco; Shiyong Li; John A Keech; Ephram P Hochberg; Matthew J Carty; Summer E Hanson; Eid Mustafa; Steven Sanchez; John T Manning; Zijun Y Xu-Monette; Alonso R Miranda; Patricia Fox; Roland L Bassett; Jorge J Castillo; Brady E Beltran; Jan Paul de Boer; Zaher Chakhachiro; Dongjiu Ye; Douglas Clark; Ken H Young; L Jeffrey Medeiros
Journal:  J Clin Oncol       Date:  2013-12-09       Impact factor: 44.544

Review 6.  Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases.

Authors:  Garry S Brody; Dennis Deapen; Clive R Taylor; Lauren Pinter-Brown; Sarah Rose House-Lightner; James S Andersen; Grant Carlson; Melissa G Lechner; Alan L Epstein
Journal:  Plast Reconstr Surg       Date:  2015-03       Impact factor: 4.730

7.  Primary non-Hodgkin's lymphomas of the female breast.

Authors:  R Giardini; C Piccolo; F Rilke
Journal:  Cancer       Date:  1992-02-01       Impact factor: 6.860

8.  Seroma-associated primary anaplastic large-cell lymphoma adjacent to breast implants: an indolent T-cell lymphoproliferative disorder.

Authors:  Anja C Roden; William R Macon; Gary L Keeney; Jeffrey L Myers; Andrew L Feldman; Ahmet Dogan
Journal:  Mod Pathol       Date:  2008-01-25       Impact factor: 7.842

Review 9.  Breast Implant-Associated Lymphoma.

Authors:  Julian Kricheldorff; Eva Maria Fallenberg; Christine Solbach; Claudia Gerber-Schäfer; Christoph Rancsó; Uwe von Fritschen
Journal:  Dtsch Arztebl Int       Date:  2018-09-21       Impact factor: 5.594

Review 10.  Breast implant-associated anaplastic large cell lymphoma: a review.

Authors:  Andrés E Quesada; L Jeffrey Medeiros; Mark W Clemens; Maria C Ferrufino-Schmidt; Sergio Pina-Oviedo; Roberto N Miranda
Journal:  Mod Pathol       Date:  2018-09-11       Impact factor: 7.842

View more
  4 in total

Review 1.  Advising patients about breast implant associated anaplastic large cell lymphoma.

Authors:  Christopher S Parham; Summer E Hanson; Charles E Butler; M Bradley Calobrace; Raylene Hollrah; Terri Macgregor; Mark W Clemens
Journal:  Gland Surg       Date:  2021-01

2.  Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-Associated Anaplastic Large-Cell Lymphoma.

Authors:  Elaine S Jaffe; Binita S Ashar; Mark W Clemens; Andrew L Feldman; Philippe Gaulard; Roberto N Miranda; Aliyah R Sohani; Timothy Stenzel; Sung W Yoon
Journal:  J Clin Oncol       Date:  2020-02-11       Impact factor: 44.544

3.  Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel STAT3-JAK2 fusion among other activating genetic alterations within the JAK-STAT pathway.

Authors:  Andrés E Quesada; Yanming Zhang; Ryan Ptashkin; Caleb Ho; Steven Horwitz; Ryma Benayed; Ahmet Dogan; Maria E Arcila
Journal:  Breast J       Date:  2021-02-18       Impact factor: 2.431

4.  UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group.

Authors:  Philip Turton; Dima El-Sharkawi; Iain Lyburn; Bhupinder Sharma; Preethika Mahalingam; Suzanne D Turner; Fiona MacNeill; Laura Johnson; Stephen Hamilton; Cathy Burton; Nigel Mercer
Journal:  Br J Haematol       Date:  2020-11-22       Impact factor: 6.998

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.